Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05166694 · ClinicalTrials.gov registry record · NA
Evaluating Personalized Therapeutics Clinic (PTC) on Drug-Drug Interactions and Drug-Gene Interactions
A NA study of Cancer and Advanced Solid Tumor, sponsored by University of Chicago.
- Recruiting
- Registry status
- NA
- Development phase
- 1,300
- Enrollment target
- 1
- Study location
NCT05166694: Recruiting NA study of Cancer and Advanced Solid Tumor, sponsored by University of Chicago.
NCT05166694 is a NA study of Cancer and Advanced Solid Tumor that is actively recruiting participants, run by University of Chicago. The registered enrollment target is 1,300 participants, below the 3,489-participant average among 615 other Cancer trials with a reported enrollment target (63% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05166694, a NA study of Cancer and Advanced Solid Tumor, is actively recruiting participants, sponsored by University of Chicago.
- RECRUITING
- Registry status
- NA
- Development phase
- 1,300 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to determine whether a consultation with a Personalized Therapeutics Clinic, or PTC, will help participants lower the risk for side effects (drug-drug interactions and drug-gene interactions) when taking many medications and help providers improve prescribing decisions for participants. A PTC is a clinical that will test your genes to gather information about your health that may help guide prescribing advice and offer you new information about your prescriptions. Doctors leading this study will look for variations (differences) in your genes that may suggest that you are at greater risk of having side effects or a greater chance of benefiting from certain medications. Individuals in this study will participate for roughly 9 months.
Primary Outcome
The change in the composite rate of drug-drug interactions (DDIs) and drug-gene interactions (DGIs) from baseline (at beginning of study) and after each intervention compared between all three arms.
Conditions Studied
Interventions
- OTHER Standard of Care
- OTHER Drug-Drug Interaction Profile
- OTHER Drug-Gene Interaction Profile
Study Locations (1)
Illinois
- University of Chicago Medicine - Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,300 participants |
| Start Date | 2022-11-30 |
| Est. Completion | 2027-11-01 |
| Phase | NA |
What NCT05166694 shows while recruiting
NCT05166694 is an interventional study that assigns participants to a tested intervention. Its 1,300 participants enrollment target places it among the larger protocols in the corpus, below the 3,489-participant average among 615 other Cancer trials with a reported enrollment target (63% lower).
The record links to 5 conditions, with Cancer appearing as the primary indexed condition, and to 3 interventions - of which Standard of Care is the first listed.
NCT05166694 reports a single indexed study location in Illinois.
Frequently Asked Questions
What is clinical trial NCT05166694 about?
NCT05166694 is a clinical study titled "Evaluating Personalized Therapeutics Clinic (PTC) on Drug-Drug Interactions and Drug-Gene Interactions". The purpose of this study is to determine whether a consultation with a Personalized Therapeutics Clinic, or PTC, will help participants lower the risk for side effects (drug-drug interactions and drug-gene interactions) when taking many medications and help providers improve prescribing decisions f...
What is the current status of trial NCT05166694?
This trial is currently recruiting. It is a NA study. The enrollment target is 1,300 participants. The study started on 2022-11-30. Estimated completion is 2027-11-01.
What conditions does trial NCT05166694 study?
This clinical trial studies the following conditions: Cancer, Advanced Solid Tumor, Advanced Cancer, Mental Health Issue, Behavior Disorders.
What interventions are being tested in trial NCT05166694?
The interventions under investigation include: Standard of Care (OTHER), Drug-Drug Interaction Profile (OTHER), Drug-Gene Interaction Profile (OTHER).
Who is sponsoring clinical trial NCT05166694?
This trial is sponsored by University of Chicago, which has 796 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05166694 being conducted?
This trial has 1 study location across Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05166694's enrollment target sits among peer trials
1,300 75th of 615 higher than 541 of 615 other Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
IMPACT (IMproving Proactive Approaches for Cancer Survivors' Mental Health Treatment)
RECRUITING · NA
-
BfedBwell Optimization Pilot
RECRUITING · NA
-
Legal Evaluation for Greater Access to Cancer Care (LEGAL-CARE)
RECRUITING · NA
-
Optimizing the AYA Survivors' Coping and Emotional Needs Toolkit
RECRUITING · NA
-
Comprehensive Connected Cancer Care (C4): Intervention Evaluation
RECRUITING · NA
-
Cancer-related Fatigue and Its Biological Contributors in Adolescent and Young Adult Brain Tumor Survivors: Effects of a Tele-exercise Intervention
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04474223 · 1,300 participants · Phase 3
Surveillance and Treatment to Prevent Fetal Atrioventricular Block Likely to Occur Quickly (STOP BLOQ)
- NCT04792684 · 1,300 participants
Collection of Samples USOPTIVAL Study
- NCT05282654 · 1,300 participants · NA
Real-time Symptom Monitoring Using ePROs to Prevent Adverse Events During Care Transitions
- NCT05705401 · 1,300 participants · Phase 3
Testing Radiation and HER2-targeted Therapy Versus HER2-targeted Therapy Alone for Low-risk HER2-positive Breast Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI